drugset
drugset / Trial / NCT05944224

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

NCT05944224 ↗

Phase 1/2 Recruiting 63 enrolled Shanghai Pharmaceuticals Holding Co., Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.

Timeline

Start
2023-10-17
Primary completion
2026-05-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadonilimab Monoclonal antibody 6 mg/kg Intravenous
Subject SPH4336 Unknown 400 mg Oral

Indications

cancer